Loading stock data…
Vivani Medical (VANI)
$1.36-0.13 (-8.39%)
Market OpenUpdated 2:23 PM EDT
Vivani Medical, Inc., a clinical-stage biopharmaceutical company, engages in the development of miniaturized and subdermal drug implants that treat chronic diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Vivani Medical, Inc. in the Healthcare sector is trading at $1.36 with a market capitalization of $104M. Wall Street consensus targets $3.83 (3 analysts), implying a +180.8% move over the next 12 months. The stock is currently 29% below its 52-week high of $1.92, remaining 6.6% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +180.8% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$6.82M↓ | -$6.81M↓ | -$6.72M↑ | -$7.46M↓ | -$6.56M |
| Net Income | -$6.78M↓ | -$6.63M↓ | -$6.53M↑ | -$7.14M↓ | -$6.30M |
Peer Comparison
JNJUNHPFE
Fundamentals
Vivani Medical, Inc., a clinical-stage biopharmaceutical company, engages in the development of miniaturized and subdermal drug implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commer...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$103.91M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-141.93%
Volume
Today's trading volume
409,953
Recent News
Has Novo Nordisk Finally Found the Catalyst That Could Flip the Script on Eli Lilly?
Novo Nordisk is leaning into convenience as it tries to regain its lead in the GLP-1 weight-loss space.
Vivani Medical Eyes August Human Trial for Semaglutide Implant After Novo Nordisk Deal
Vivani Medical (NASDAQ:VANI) said it is preparing to begin human testing of its semaglutide implant in August and highlighted a recently announced agreement with Novo Nordisk to evaluate the company’s implant technology. Adam Mendelsohn, co-founder, CEO and director of Vivani Medical, said the past
Novo Nordisk (CPSE:NOVO B) Could Be 13% Overvalued Following Its Vivani Deal
Vivani Medical’s new agreement gives Novo Nordisk (CPSE:NOVO B) access to evaluate NPM-139, a semaglutide implant for chronic weight management, offering investors another data point on the company’s obesity drug delivery options. See our latest analysis for Novo Nordisk. The Vivani agreement lands at a time when Novo Nordisk’s DKK323.15 share price has shown strong short term momentum, with a 30 day share price return of 18.81% and a 90 day share price return of 35.72%. Over longer periods,...
Novo Nordisk signs pact with Vivani for long-lasting semaglutide implant
Vivani’s NanoPortal technology delivers medication steadily over long periods of time.
Novo Nordisk (CPSE:NOVO B) Teams Up With Vivani To Test A Semaglutide Implant
Novo Nordisk and Vivani Medical are collaborating to evaluate a semaglutide drug implant using Vivani’s NanoPortal platform for chronic weight management. Vivani has initiated a Phase 1 clinical study of the implant, while Novo Nordisk assesses semaglutide in this drug delivery format. The partnership focuses on an implantable GLP-1 approach that could offer an alternative to pills and injections for obesity treatment. Novo Nordisk, traded as CPSE:NOVO B, is already a central player in...